RecruitingNCT06657378

A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures

A Multicenter, Postmarketing Observational (Noninterventional) Study to Evaluate the Safety of Fycompa for Injection in Patients With Partial-Onset Seizures (Including Secondarily Generalized Seizures) (Age 4 Years or Older) or Primary Generalized Tonic- Clonic Seizures (Age 12 Years or Older)


Sponsor

Eisai Co., Ltd.

Enrollment

110 participants

Start Date

Nov 18, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures \[including secondarily generalized seizures\]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).


Eligibility

Min Age: 4 Years

Inclusion Criteria1

  • Participants with epilepsy who received the Fycompa for injection for the first time will be included.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo Intervention

This is a non-interventional study.


Locations(1)

1

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06657378


Related Trials